FirsthandHealth
medRxiv PreprintsInternational17 November 2026

Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary end
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.